摘要
Objective To systematically examine the effectiveness and tolerability of psilocybin for treating end-of-life anxiety symptoms. Methods The Medline, Embase, CENTRAL, and PsycINFO databases were searched up to November 25, 2020. We enrolled clinical trials investigating psilocybin for treating end-of-life anxiety symptoms. Meta-analysis was conducted using random-effects model. Results Overall, five studies were included, revealing that psilocybin was superior to the placebo in treating state anxiety at 1 day (Hedges’ g,-0.70; 95% confidence interval,-1.01 to-0.39) and 2 weeks (-1.03;-1.47 to-0.60) after treatment. Psilocybin was more effective than placebo in treating trait anxiety at 1 day (-0.71;-1.15 to-0.26), 2 weeks (-1.08;-1.80 to-0.36), and 6 months (-0.84;-1.37 to-0.30) after treatment. Psilocybin was associated with transient elevation in systolic (19.00; 13.58–24.41 mm Hg) and diastolic (8.66; 5.18–12.15 mm Hg) blood pressure compared with placebo. The differences between psilocybin and placebo groups with regard to all-cause discontinuation, serious adverse events, and heart rates were nonsignificant. Conclusion Psilocybin-assisted therapy could ameliorate end-of-life anxiety symptoms without serious adverse events. Because of the small sample sizes of the included studies and high heterogeneity on long-term outcomes, future randomized controlled trials with large sample sizes are needed.
| 原文 | 英語 |
|---|---|
| 頁(從 - 到) | 958-967 |
| 頁數 | 10 |
| 期刊 | Psychiatry Investigation |
| 卷 | 18 |
| 發行號 | 10 |
| DOIs | |
| 出版品狀態 | 已出版 - 10 2021 |
文獻附註
Publisher Copyright:© 2021 Korean Neuropsychiatric Association.
UN SDG
此研究成果有助於以下永續發展目標
-
SDG3 健康與福祉
指紋
深入研究「Psilocybin for end-of-life anxiety symptoms: A systematic review and meta-analysis」主題。共同形成了獨特的指紋。引用此
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver